REGENXBIO Inc. Files 8-K: Officer/Director Changes & Compensation
Ticker: RGNX · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1590877
Sentiment: neutral
Topics: management-change, compensation, disclosure
TL;DR
REGENXBIO leadership shuffle and comp changes filed.
AI Summary
REGENXBIO Inc. filed an 8-K on September 17, 2024, reporting events as of September 16, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD Disclosures and Financial Statements and Exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation can signal internal shifts that may affect future performance or strategy.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- September 17, 2024 (date) — Date of Report
FAQ
What specific officer or director positions were affected by the events reported on September 16, 2024?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
Are there any new compensatory arrangements for officers detailed in this filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, suggesting such arrangements are part of the report, though specifics are not in the excerpt.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making public disclosures to ensure broad public dissemination of material non-public information, as required by Regulation FD.
Does this 8-K filing include any financial statements?
Yes, the filing lists 'Financial Statements and Exhibits' as an item, suggesting that financial information is included.
What is REGENXBIO Inc.'s primary business sector?
REGENXBIO Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, with SIC code 2836.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2024-09-17 17:00:23
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
- $3 billion — cessful initial public offering and its $3 billion acquisition by Horizon Therapeutics. Pr
- $490,000 — ly will be entitled to a base salary of $490,000 and annual bonus target will be establi
- $3,000,000 — h an aggregate grant date fair value of $3,000,000, of which approximately 75% will consis
- $500,018 — will receive a separation allowance of $500,018 to be paid in three equal installments
Filing Documents
- rgnx-20240916.htm (8-K) — 48KB
- rgnx-ex99_1.htm (EX-99.1) — 20KB
- img101737798_0.jpg (GRAPHIC) — 16KB
- 0000950170-24-107367.txt ( ) — 209KB
- rgnx-20240916.xsd (EX-101.SCH) — 24KB
- rgnx-20240916_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 17, 2024, the Company issued a press release announcing the transition of the Company's Chief Financial Officer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated September 17, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: September 17, 2024 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer